Introduction
Alzheimer's disease (AD) is characterized by a progressive deterioration of cognitive abilities, eventually leading to the individual's death. 1 Accumulation of the amyloid-b-peptide (Ab), a product obtained by processing the amyloid precursor protein (APP), is believed to have a key function in the cognitive deficits observed in AD. 2 AD is also characterized as a synaptic disease that causes decreases in synaptic proteins and alterations in synaptic function. [3] [4] [5] [6] Lithium compounds are used in the treatment of various bipolar spectrum disorders, and have been shown to have neuroprotective effects against various insults. 7, 8 In addition, they inhibit enzyme glycogen synthase kinase-3b (GSK-3b), leading to an increase in intracellular b-catenin and to the consequent activation of the Wnt-b-catenin signaling pathway. 9 Interestingly, the inhibition of GSK-3b has been shown to protect against Ab neurotoxicity in mice models of AD. 10, 11 Previously, we have shown in a rat model of AD, by directly injecting Ab fibrils into the hippocampal regions, that lithium treatment resulted in the improvement of spatial memory and in decreased glial inflammatory reaction, most likely by the activation of the Wnt signaling pathway. 12 Moreover, therapeutic concentrations of lithium interfere with the APP cleavage at the g-secretase level and reduce the amyloid burden in the brain of transgenic mice models of AD. 13, 14 The peroxisome proliferator activated receptor-g (PPARg) is a member of the family of PPAR nuclear receptors, with an important role in the regulation of lipid metabolism. 15 PPARg agonists have been shown to attenuate Ab neurotoxic effects by increasing the clearance mechanism of Ab peptide or by cross talking with the Wnt signaling pathway. 16, 17 Exposure of PC12 cells to ApoE4 (apolipoprotein E4) resulted in an inhibition of Wnt signaling, 18 and could therefore also reduce PPARg activation. Moreover, it has been shown that treatments with rosiglitazone, a PPARg agonist, in AD patients (ApoE4 À/À ) lead to an improvement in cognitive test scores. 19 In addition, rosiglitazone improves learning and memory in transgenic mice with the Swedish mutation (APP K595N/M596L, APPswe). 20 Interestingly, rosiglitazone increases dendritic spine density and prevents spine loss caused by ApoE4 in cortical neurons, 21 indicating that it may have protective effects against the cognitive damage observed in AD.
In this study, we have examined the in vivo effects of lithium and rosiglitazone on Ab neurotoxicity using a double transgenic mouse model that coexpresses APPswe and the exon 9 deletion of the presenilin 1 (PSEN1) gene. 22 Mice were tested for spatial memory, and their brain samples were used for biochemical and histochemical analysis. In this study, we report that lithium-and rosiglitazonetreated transgenic mice have significant improvements in spatial memory, and they showed lower levels of Ab in hippocampal and cortical brain areas of both Ab aggregates and Ab oligomers. A reduced astrogliosis and microglial activation was also observed in both groups. In addition, the levels of presynaptic and postsynaptic marker proteins, which diminished in transgenic control mice, were maintained even after treatment with lithium and rosiglitazone.
Materials and methods

Reagents and antibodies
The following primary antibodies were used: rabbit anti-glial fibrillary acidic protein (GFAP) (DAKO, Carpinteria, CA, USA), mouse anti-Ab (6E10, Chemicon, Temecula, CA, USA) and mouse monoclonal anti-postsynaptic density-95 (PSD95) (clone K28/43, obtained from Antibodies Inc.; Neuromab, Davis, CA, USA), rabbit anti-tubulin (Santa Cruz Biotechnology, Santa Cruz, CA, USA), mouse anti-b-catenin (Santa Cruz Biotechnology), rabbit anti-VAMP1-2 (Santa Cruz Biotechnology) and rabbit anti-b-tubulin (Santa Cruz Biotechnology), rabbit anti-GSK-3b and antiphospho-Ser9-GSK-3b (Cell Signaling Technology, Danvers, MA, USA). The reagents used were as follows: Rosiglitazone maleate (Avandia; GlaxoSmithKline, Brentford, UK) and lithium chloride (Sigma Chemicals, St Louis, MO, USA).
Subjects
Four-month-old APPswe/PSEN1DE9 (known as APP-PS1 henceforth in this study) bigenic mice were purchased from Jackson Laboratory (Bar Harbor, ME, USA; Stock no. 004462). Wild-type (C57/BL) animals were also obtained from a colony of the Animal House Facility of the Facultad de Ciencias Biologicas (P. Universidad Catolica de Chile). All the animals were housed in temperature-and light-controlled rooms, with food and water ad libitum until the end of treatments. The animals were administered intraperitoneal (IP) injections of lithium chloride daily, dissolved in saline serum, or with rosiglitazone by oral gavage. Rosiglitazone maleate (Avandia) was ground and used as a suspension in sterile water. Control treatments included IP injections of saline solution or maleate in sterile water by gavage (0.45 mg ml
À1
). There was no associated morbidity/ mortality with daily IP injections of lithium at this dosage. No differences were found between transgenic mice and controls with IP injection, gavage or without treatment. The data of the transgenic control animals were polled and labeled as transgenic controls.
Behavioral test
The Morris water maze was performed as previously described in our laboratory. 12, 23, 24 The memory flexibility test was conducted as described by Chen et al. 25 Briefly, mice were trained in a circular water maze of 1.2 m diameter (opaque water, 50 cm deep, 19-21 1C, 9-cm platform 1 cm below water, maximum trial duration 60 s, 10 s on platform at the end of trials). Each animal was trained for one pseudo-random location of the platform per day, for 4 days, with a new platform location each day. Training was conducted up to 10 trials per day, until the criterion of 3 successive trials with an escape latency of < 20 s was met. On completion of testing, the mouse was removed from the maze, dried and returned to its cage. The animals were tested for the next location on the following day. Data were collected using a video tracking system for water maze (HVS Imagen, Hampton, UK).
Immunohistochemical procedures
Perfusion and fixation were performed as previously described. 12, 26 Free-floating immunohistochemical procedures were carried out as previously described. 26, 27 Washing and dilution of immunoreagents were carried out using 0.01 M PBS (phosphatebuffered saline) with 0.2% Triton X-100 (PBS-T) throughout the experiments, with two PBS-T washes per antibody incubation. Sections were pretreated with 0.5% H 2 O 2 for 30 min to reduce endogenous peroxidase activity, followed by treatment with 3% bovine serum albumin at room temperature for 1 h to avoid nonspecific binding. Primary antibodies were incubated overnight at 4 1C. They were detected using the Pierce ABC Kit (Thermo Fisher Scientific Inc., Rockford, IL, USA). Staining was performed by incubating for 15 min with 0.6% diaminobenzidine, followed by the addition of H 2 O 2 (0.01% final concentration). After immunostaining, all sections were mounted on gelatin-coated slides, air-dried, dehydrated and coverslipped with Canada balsam (Merck, Darmstadt, Germany). ThS (thioflavin S) staining was performed as previously described. 24, 26, 27 BSB ([(trans,trans)-1-Bromo-2,5-bis-(3-hydroxycarbonyl-4-hydroxy)-styrylbenzene) staining was performed as described earlier. 28, 29 Briefly, the mounted sections were dehydrated and rehydrated in graded ethanol solutions, stained with BSB solution (200 mM) in 50% ethanol for 30 min, washed with saturated solution of lithium carbonate, differentiated with 50% ethanol and covered using a fluorescentmounting medium.
Immunoblotting
The hippocampus and cortex of treated or control transgenic mice were dissected on ice and immediately frozen in liquid nitrogen or processed as detailed previously. 30 Briefly, hippocampal and cortex tissues were homogenized in RIPA (radioimmunoprecipitation assay) buffer (10 mM Tris-Cl, pH 7.4, EDTA (ethylenediaminetetraacetic acid) 5 mM, 1% NP-40 (Nonidet P40), 1% sodium deoxycholate and 1% SDS), supplemented with a protease inhibitor mixture (1 mM PMSF (phenylmethanesulfonyl fluoride), 2 mg ml À1 aprotinin, 1 mg ml À1 pepstatin and 10 mg ml À1 benzamidine) and phosphatase inhibitors (25 mM NaF, 100 mM Na 3 VO 4 , 1 mM EDTA and 30 mM Na 4 P 2 0 7 ) using a Potter homogenizator, and then passed sequentially through different caliber syringes. Protein samples were centrifuged at 14 000 r.p.m. at 4 1C twice for 5 min. Protein concentrations were determined using the BCA Protein Assay Kit (Pierce). A total of 30 mg of hippocampal and cortex tissue samples were resolved by 12% SDS-PAGE, followed by immunoblotting on polyvinylidene difluoride membranes using mouse anti-PSD95 (Neuromab, Davis/NIH NeuroMab Facility, Davis, CA), rabbit anti-vesicle-associated membrane protein (VAMP), mouse anti-b-catenin, goat anti-synaptophysin, mouse anti-dishevelled-3 or rabbit anti-b-tubulin antibodies (Santa Cruz Biotechnology), rabbit anti-GSK-3b, rabbit anti-Ser9-GSK-3b (Cell Signaling Technology). Western blot assays were carried out as previously described. [31] [32] [33] Slot-blots assays were performed as previously described. 34 Briefly, the total protein extract was centrifuged to eliminate fibrillar aggregates at 20 000 g for 1 h. The protein concentration of the soluble fraction was determined and 6 mg of protein was spotted in 0.45 mm 2 nitrocellulose (Millipore, Bedford, MA, USA), blocked with PBS-T gelatin 0.4% and incubated using an anti-oligomeric antibody A11 (Chemicon) 1/5000 for 4 h at 4 1C. Slot blots were revealed with the same methodology as used for western blot.
Image analysis
The stained brain sections were photographed using an Olympus BX51 microscope coupled to a Micropublisher 3.3 RTV camera (QImaging, Surrey, BC, Canada). The luminance of the incident light and the time of exposure were calibrated to assign pixel values ranging from 0 to 255 in an red-green-blue image (no-light to full-light transmission), a setting that was used along all preparations. The images were loaded into ImageJ v.1.42d software (National Institutes of Health, Bethesda, MD, USA) for analysis. Selection of areas for measurement was performed by manual threshold adjustment. Quantifications were performed blindly in six coronal sections per animal, spaced 180 mm apart. Average optical densities were measured in 8-bit converted images. The analysis of each slot-blot picture was carried out by normalizing for the average intensity of control APP-PS1 slots in each experiment.
Statistical analysis
Data analysis was carried out using Prism software (GraphPad Software Inc., La Jolla, CA, USA). Results were expressed as mean ± s.e. For statistical analysis, normally distributed data were analyzed by one-way ANOVA (analysis of variance) with post hoc tests performed using the Tukey test. Non-normally distributed data were analyzed by the Kruskal-Wallis test, with post hoc tests conducted using Dunn's test.
Results
Treatments of lithium and rosiglitazone reduce spatial memory loss in double transgenic mice Double transgenic mice that express mutant APP SWE (K595N/M596L) and PS1 (PSEN1DE9: deletion of the exon 9) were used, producing depositions of Ab plaques in the cortex and hippocampus in an age-and region-dependent manner. 35 These mice and agematched wild types were used to analyze how physiopathological markers of AD were modified by lithium (3 mequiv. kg À1 IP, daily) and rosiglitazone (3 mg kg À1 gavage, daily) treatments initiated at 9 months of age. To determine the steady-state concentration of lithium in our regime of treatment, plasma lithium concentrations were measured in a separate group of animals. The therapeutic plasmatic concentrations are in the range of 0.2-1.5 mequiv. l
À1
. 36 Plasma concentration was 0.225 mequiv. l À1 24 h after lithium injection ( Supplementary Information,  Figure 1 ), below toxic concentrations and in the range of therapeutic concentration. 37 Hippocampal function was tested through a spatial memory test known as the Morris water maze. After 12 weeks of treatment, high variability was observed, and no clear difference among the animals groups was detected (Figure 1a ). Therefore, a more sensitive version of the Morris water maze, which measures memory flexibility, was evaluated 25 This modified version of the spatial memory Morris water maze has proven to be more sensitive to hippocampal dysfunctions. 25, 38 In this task, mice are required to learn a series of spatial locations successively, one at the time, testing for an episodic-like component of encoded location. 39 A deficit in the number of trials required to reach the escape criterion was found at each of the four platform locations for the APP-PS1 control mice. As observed in Figure 1b , treated animals required a significantly reduced number of trials to reach criterion, and this improvement in spatial memory almost reached wild-type levels ( Figure 1c) . A post hoc analysis of the data shows that treated APP-PS1 animals have improved memory flexibility than untreated APP-PS1 mice. When the strategies used by the animals to reach the platform were compared at day 4 (times < 20 s), it was possible to appreciate the difference between wild-type animals and APP-PS1 controls. In fact, treated animals showed improved strategies compared with APP-PS1 controls. Treated APP-PS1 animals presented strategies that were more similar to those by wild-type animals than the transgenic controls (Figure 1d) . Our behavioral analysis indicates that lithium and rosiglitazone reduce the deficit in spatial memory observed in these APP-PS1 transgenic mice.
Ab plaque size in APP-PS1 mice is reduced with lithium and rosiglitazone treatment To examine whether the improvement in mice behavior was correlated with a change in AD neuropathological markers, we analyzed the amount of Ab plaques present in the brains of APP-PS1 animals. Brain sections obtained from lithium-, rosiglitazone-and vehicle-treated mice were stained with an antibody against Ab and analyzed for Ab burden present in cortical and hippocampal regions (Figure 2a-f) . The APP-PS1 brain sections showed a reduction in the positive area for Ab aggregates in treated animals versus controls in the cortex and hippocampus (Figure 2g and h) . A detailed analysis of the plaque size distribution of the Ab area was also carried out. The aggregate size distribution was presented as a cumulative plot, which showed that APP-PS1 mice treated with lithium and rosiglitazone had an increased number of small plaques in both the cortex (0.6 < mm 2 ) and hippocampus, although still maintaining smaller overall plaque loads in these regions (Figure 2i-j) . With the use of antibodies against Ab, all kinds of positive areas in the cortex and hippocampi were detected and considered in the quantification.
To identify whether lithium or rosiglitazone alters the amount of amyloid b-sheet deposits present, brain sections from wild-type mice, APP-PS1 control, APP-PS1 lithium-and APP-PS1 rosiglitazone-treated mice were stained with ThS and analyzed for the area fraction positive to ThS and plaque density (Figure  3a-f) . This analysis showed a reduction in the positive area to ThS and in the number of plaques per area in both treatments (Figure 3g and h ). This result is in agreement with the findings that lithiumand rosiglitazone-treated groups had a reduction in the overall amount of Ab aggregates detected using antibodies against Ab. 
Lithium and rosiglitazone treatment reduces inflammatory reaction in double transgenic mice
In an attempt to understand the mechanism by which lithium and rosiglitazone affect Ab aggregates, the astroglial inflammatory reaction normally observed in brains with Ab plaques was studied. Brains sections from vehicle-, lithium-and rosiglitazone-treated mice were stained against GFAP and analyzed for the presence of hypertrophic glial cells (Figure 4a-h) . A detailed analysis was conducted including the ). Astroglial GFAP intensity in the cortex and hippocampus was also significantly reduced in lithium-and rosiglitazone-treated mice in comparison with that in control transgenic mice, and showed intensities similar to those of wild-type mice (Figure 4i and j lower panels) . The microglial component of the inflammatory response was also analyzed. Sections of all experimental groups were stained against the CD11b marker. The analysis of the area that is positive for CD11b showed that the area fraction of control APP-PS1 mice was significantly higher in comparison with that in treated animals (Figure 5a and f) , in the cortex (Figure 5g ) and hippocampus (Figure5h). The above results indicate that the inflammatory response found in APP-PS1 mice is reduced on treatment with lithium and rosiglitazone.
Lithium and rosiglitazone recover the loss of synaptic proteins Previous studies have indicated that synaptic disturbances are present in AD brains and in transgenic animal models. [3] [4] [5] [6] 40 To further analyze the implication of lithium and rosiglitazone in the neuroprotection observed in our study, we analyzed the amount of various presynaptic and postsynaptic proteins de- tected in the hippocampus of APP swe /PSEN1DE9 mice. The presynaptic proteins, synaptophysin and VAMP, as well as the postsynaptic protein, PSD-95, showed an increase in total levels after lithium and rosiglitazone treatments (Figure 6 ), as can be seen in the densitometry analysis.
Considering the fact that the target for Ab oligomers is the postsynaptic region, 41, 42 the distribution of PSD-95 in the hippocampus was analyzed using histochemistry. High levels of PSD-95 are present in the hippocampal region of wild-type animals and, when compared with APP-PS1 control animals, it is possible to detect a loss of PSD-95 staining in the CA3 stratum lucidum region of the hippocampus (Figure 7a and b) . However, this change was recovered in brains sections of treated animals (Figure 7c and d), as can be observed in the densitometry analysis of these regions (Figure 7e ), thus indicating that both treatments are capable of preventing the decrease in postsynaptic proteins found in the hippocampus of APP-PS1 animals.
Wnt signaling activation reduces the amount of Ab oligomers in the hippocampus As oligomeric aggregates of Ab have proven to be synaptotoxic 4 and reduce synaptic function in vitro and in vivo, [42] [43] [44] [45] we decided to evaluate the amount of Ab oligomers present in brains of APP-PS1 mice. First, we assessed the areas and distribution of aggregate positives with BSB, a derivative of Congo Red that is more prone to stain oligomers than fibrils. 29 Brain sections from wild-type mice, APP-PS1 control, APP-PS1 lithium-and APP-PS1 rosiglitazone-treated mice were stained with BSB and analyzed for area fraction and plaque density (Figure  8a-f) . This analysis showed a reduction in the positive area of BSB staining in the hippocampus by both treatments (Figure8h) . However, in the cortex, we did not find a change in the area of positive aggregates with both treatments (Figure 8g) . Neither treatment showed a reduction in the numbers of positive aggregates per area (data not shown). Slotblot assays were carried out to assess the amounts of Ab oligomers detected by the antibody A11, which detect oligomeric aggregates with a mass over 40 kDa. 46 Hippocampal extracts obtained from APP-PS1 animals, control and treated, were blotted in a nitrocellulose membrane and detected with the A11 antibody (Figure 8i ). The densitometry analysis showed a significant reduction in the levels of oligomeric species detected in the hippocampi of APP-PS1 mice with both treatments (Figure 8j ).
The reduction of Wnt signaling is prevented by lithium and rosiglitazone Previous studies in our laboratory have indicated that Wnt signaling activation is related to neuroprotection against Ab injury. 5, 12, 31, [47] [48] [49] [50] Considering that lithium is a pharmacological activator of the Wnt signaling pathway and rosiglitazone is a PPARg agonist that activates Wnt signaling by cross talk, 5, 17 we wanted to confirm that under our experimental conditions, Wnt signaling was in fact activated. The expression of Wnt key proteins was analyzed by western blotting. These results indicated that APP-PS1 mice have lower levels of Dvl-3 and b-catenin, and increased levels of activated GSK-3b than do wild-type animals ( Figure 9 ). These results showed a reduction in canonical Wnt signaling in this model of AD. The APP-PS1 mice treated with lithium showed a recovery in the levels of b-catenin and Dvl-3, and increased levels of the inhibited GSK-3b (Figure 9 ). Rosiglitazone showed a clear recovery in the levels of bcatenin and increased levels of the inactive GSK-3b; however, no effect was observed in Dvl-3 levels. These results strongly suggest that lithium and rosiglitazone activate Wnt signaling in vivo.
Discussion
In this study, we showed that transgenic mice APPswe/PSEN1DE9 had a deficit in spatial memory, which could be partially restored to wild-type levels by treatment with both lithium and rosiglitazone. The observed increase in Ab loads as well as the increased astrogliosis present in the transgenic control mice, is correlated with impairment in their spatial memory. However, treatment with lithium and rosiglitazone prevents the aforementioned changes.
Lithium is a common drug used for the treatment of bipolar spectrum disorders, 51 and it possesses a great potential for the treatment of numerous other pathologies. 52 One of lithium's interesting mechanisms of action is its inhibition of the enzyme GSK-3b, which mimics the effect of activation of canonical Wnt signaling. 9, 53 Previously, it was found that treatment with lithium protects against different insults; 7, 54 however, the relationship between an inhibition of this enzyme and lithium in vivo has been insufficiently explored. Lithium was previously reported to reduce the amount of phosphorylated t in vitro 55 and in vivo. 10, 56 Using a transgenic model of AD, it was shown that the decrease in the phosphorylation of t occurs without affecting the amount of Ab plaques or memory impairment. 57 However, those studies were carried out in a triple transgenic model that expresses a mutated form of the t-protein, in addition to the mutated forms of APP and PS1. It is quite possible that overexpression of a mutated form of t-protein is a pathological feature that the treatment of lithium cannot overcome.
Peroxisome proliferator activated receptor-g agonists have been found to protect against Ab toxicity in neurons. 17, 58, 59 Mechanisms that have been associated with some PPARg agonists include decreased glial inflammation through the decreased expression of proinflammatory enzymes, such as cyclooxygenase 2 and the inducible nitric oxide synthase. 60 The underlying mechanism of rosiglitazone remains unclear. Although rosiglitazone is capable of increasing the clearance mechanism of the Ab peptide, 16 activation of the Wnt signaling, 17 it is not clear whether the neuroprotection attributed to rosiglitazone is because of its PPARg agonist activity or its downstream effects. At least three possible scenarios can be attributed to its neuroprotective effects: first, a direct activation of PPARg genes; second, non-genomic effects of the PPARg activation; and finally, cross talk with another pathway, that is, the Wnt pathway. Further research is necessary to analyze the presented possibilities. The APP-PS1 mice treated with rosiglitazone did not show increased levels of Dvl-3, but showed increased levels of b-catenin and the inhibited form of GSK-3b, and as Dvl-3 is activated right after the binding of Wnt to the receptor, 61, 62 this result may help to reveal a part of the mechanism of the cross talk. 63 Our results indicate that APP-PS1 mice treated with lithium and rosiglitazone had a significantly lower area occupied by plaques than did transgenic control mice. Furthermore, when plaques were analyzed for their size distribution, we observed that APP-PS1 mice treated with lithium and rosiglitazone had a higher amount of small plaques ( < 0.5 mm 2 ) in both the cortex and hippocampus as compared with transgenic controls. It was previously reported that lithium has the ability to inhibit Ab production, limiting plaque growth. 13 Furthermore, PPARg agonists have shown their ability to reduce levels of secreted Ab in vitro. 16 The potential mechanism to limit the size of Ab found in both treatments could be attributed in part to a reduced production of the Ab peptide.
The analysis of the nature of plaques present in transgenic brains indicated that treatments reduce the amount of total aggregates, plaques and oligomers, suggesting that the reduction observed is probably because of an increase in disassembly, clearance and/ or catabolism of Ab aggregates, and therefore it is possible that Wnt signaling activation increases an active Ab clearance mechanism that, under normal conditions, could be found at a basal activity. 64 Of the described mechanism of Ab catabolism, 65 the observed effect could be attributed to metalloproteinases (MMPs). MMP activity, mainly in astrocytes and microglia, is able to degrade oligomeric and fibrillar aggregates. [65] [66] [67] Furthermore, MMP-2 and MMP-9 are identified as Wnt target genes in T cells; 68 MMP-7 is a Wnt target gene in colon rectal cancer. 69, 70 Moreover, the inhibition of GSK-3b by Akt leads to an increased level in the activity of MMP. 71 All this evidence suggests that Wnt activation could restore a . Slot-blot analysis from hippocampal extracts using anti-oligomeric antibody A11. Representative slot blot picture, 6-mg protein per slot was spotted to a nitrocellulose membrane and exposed to the A11 antibody (i). Normalized densitometric analysis profile of each slot intensity versus distance (dotted lines), average line (black bold line) and red line average intensity of each treatment (100 pixels wide) (j). Asterisks indicate significant difference, *P < 0.05. catabolic pathway found in glial cells, probably through the action of MMP but without ruling out the actions of other catabolic activities.
Increased gliosis is a characteristic feature of brains with increased Ab loads. 72, 73 In this study, we observed that APP-PS1 control mice had a significantly increased perykarion size and GFAP intensity, which was decreased to wild-type levels in APP-PS1 mice treated with lithium and rosiglitazone. This may indicate that lithium and rosiglitazone can protect against the glial inflammatory reaction observed in AD brains, which may amplify the damage already caused by Ab plaques. In addition, the prevention of the decrease in synaptic markers found in treated mice showed that lithium and rosiglitazone prevent synaptic failure found in models of AD. 42, 43, 74, 75 These changes correlate with an enhanced performance in our memory flexibility test, suggesting that hippocampal synaptic function is improved under both treatment conditions.
Increasing evidence has shown a relationship between Wnt signaling and synaptic functions. In fact, we found that Wnt/b-catenin modulates the synaptic vesicle cycle and synaptic transmission in rat hippocampal neurons, 76 and non-canonical Wnt signaling also modulates PSD-95 clustering. 33 Therefore, these possible mechanisms needed to be explored in APP-PS1 animals treated with lithium and rosiglitazone. Recently, He and Shen 77 reported that the renewal capacity of glial progenitor cells isolated from AD patients is reduced compared with that of cells from healthy controls, and this reduced neurogenesis capacity was correlated with GSK-3b activity and an increased phosphorylation of bcatenin. They also found that treating glial precursor cells from healthy controls with Ab also led to increased b-catenin phosphorylation and reduced neurogenesis. This finding suggests that, in AD patients, Ab impairs neurogenesis and Wnt signaling has a key function in these effects.
The one question that we were unable to address in this study is whether one or both treatments can overcome the neurotoxicity of Ab at the level of synaptic spines. Dendritic spines have been found to be targets of oligomeric Ab, 6, 43 and in vivo APP and PS1 transgenic mice develop a reduction in spine density because of Ab. 45 The analysis that rosiglitazone treatments protect against the toxicity of an ApoE4 fragment and increase dendritic spine density 21 suggests that this could be a mechanism by which rosiglitazone overcomes synaptic impairment.
In summary, this study indicates that lithium and rosiglitazone treatment improves the disturbances observed in memory flexibility in the APP-PS1 model of AD. These results correlated with a reduction in the amount of Ab aggregates present and a concomitant decrease in glial inflammatory reaction, as well as an increase in presynaptic and postsynaptic proteins. More interestingly, both these compounds may induce an activation of the Wnt signaling pathways. Treated APP-PS1 mice with lithium showed increased levels of Dvl-3, and both treatments showed increased levels of b-catenin and the inhibited state of GSK-3b in APP-PS1 mice; hence, the aforementioned results could be an outcome of the increase in Wnt signaling. Our results show neuroprotection by Wnt signaling in an in vivo transgenic mouse model. Finally, our study shows that both lithium and rosiglitazone have the potential to uncover new therapeutic possibilities for the treatment of AD. 
